Press releases • Jul 11, 2019 16:26 BST
AbbVie Receives CHMP Positive Opinion for SKYRIZI™ ▼ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis in adults
Press releases • Mar 01, 2019 12:13 GMT
CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission1-3
HUMIRA® (adalimumab) 80 mg/0.8 mL Presentation intended as an Alternative Option for Therapy Induction and Maintenance Therapy is Now Available
Press releases • Dec 03, 2018 09:25 GMT
• HUMIRA citrate-free 80 mg/0.8 mL formulation reduces the number of injections required to initiate HUMIRA therapy by half • Convenient 80 mg every other week dosing for patients that require dose escalation
Press releases • Oct 16, 2018 13:22 BST
AbbVie today (16th October 2018) welcomes the intention expressed by NHS England to maintain HUMIRA® (adalimumab); a specialised biologic medicine for treating a number of inflammatory conditions, as an ongoing treatment option for physicians and patients, as part of the adalimumab tendering strategy, which will start on 1st December 2018.
AbbVie Submits Marketing Authorisation Application to the European Medicines Agency for Investigational Treatment Risankizumab for Moderate to Severe Plaque Psoriasis
Press releases • May 02, 2018 10:10 BST
• Application supported by four pivotal Phase 3 trials evaluating patients with moderate to severe plaque psoriasis (refs 1-3) • Risankizumab is an investigational compound designed to selectively inhibit IL-23 by binding to its p19 subunit (ref 4) and is being evaluated for the potential to deliver long-term skin clearance for psoriasis patients with 12-week dosing
New Presentation, HUMIRA® (adalimumab) 20 mg/0.2 mL for Injection in Pre-filled Syringe (PFS) Launched for Paediatric Patients, together with the Introduction of Fixed Weight Dosing
Press releases • Mar 29, 2018 16:06 BST
Maidenhead, UK, 29th March 2018 – AbbVie a global research and development-based biopharmaceutical company, today announced the launch of HUMIRA® (adalimumab) 20 mg/0.2 mL presentation. The presentation is designed for injection in a pre-filled syringe specifically in paediatric patients for approved indications.